Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shalabi H, Qin H, Su A, Yates B, Wolters PL, Steinberg SM, et al. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. Blood. 2022;140:451–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao Y, Aldoss I, Qu C, Crawford JC, Gu Z, Allen EK, et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood. 2021;137:471–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao L, Lv C, Sun L, Li Q, Wang Y, Wu M, et al. Histone deacetylase inhibitor chidamide regulates the Wnt/beta-catenin pathway by MYCN/DKK3 in B-ALL. Invest New Drugs. 2021;39:961–70.

Article  CAS  PubMed  Google Scholar 

Zhao L, Li S, Wei X, Qi X, Liu D, Liu L, et al. A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. Blood. 2022;140:1790–802.

Article  CAS  PubMed  Google Scholar 

Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell. 2012;148:1172–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Z, Wang C, Liu T, Tang Z, Yan R, Zhang C, et al. miRNA-182-5p promotes human bladder cancer proliferation and migration through the FOXF2/SHH axis. Neoplasma. 2022;69:321–30.

Article  CAS  PubMed  Google Scholar 

Yao H, Kong F, Zhou Y. MiR-182 promotes cell proliferation, migration and invasion by targeting FoxF2 in endometrial carcinoma cells. Int J Clin Exp Pathol. 2019;12:1248–59.

CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Zhang H, Gong H, Yuan Y, Li Y, Wang C, et al. miR-182 suppresses invadopodia formation and metastasis in non-small cell lung cancer by targeting cortactin gene. J Exp Clin Cancer Res. 2018;37:141.

Article  PubMed  PubMed Central  Google Scholar 

Yan S, Wang H, Chen X, Liang C, Shang W, Wang L, et al. MiR-182-5p inhibits colon cancer tumorigenesis, angiogenesis, and lymphangiogenesis by directly downregulating VEGF-C. Cancer Lett. 2020;488:18–26.

Article  CAS  PubMed  Google Scholar 

Wu Y, Zhang C, Peng D, He S, Huang C, Qian J, et al. MiR-182-5p inhibits the tumorigenesis of clear cell renal cell carcinoma by repressing UBE2T. Hum Cell. 2022;35:542–56.

Article  CAS  PubMed  Google Scholar 

Ye S, Xiong F, He X, Yuan Y, Li D, Ye D, et al. DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclax. Theranostics. 2023;13:77–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo SX, Taki T, Ohnishi H, Piao HY, Tabuchi K, Bessho F, et al. Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia. Leuk Res. 2000;24:39–46.

Article  CAS  PubMed  Google Scholar 

Teofili L, Martini M, Luongo M, Diverio D, Capelli G, Breccia M, et al. Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. Leukemia. 2003;17:919–24.

Article  CAS  PubMed  Google Scholar 

Duncavage EJ, Uy GL, Petti AA, Miller CA, Lee YS, Tandon B, et al. Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. Blood. 2017;129:1397–401.

Article  CAS  PubMed  PubMed Central  Google Scholar 

DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qin Y, Kuang P, Liu T. Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis. Clin Exp Med. 2023;23:219–27.

Article  CAS  PubMed  Google Scholar 

Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24:1859–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang B, Liu XX, He JR, Zhou CX, Guo M, He M, et al. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis. 2011;32:2–9.

Article  CAS  PubMed  Google Scholar 

Song MG, Gao SM, Du KM, Xu M, Yu Y, Zhou YH, et al. Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms. Blood. 2005;105:3714–21.

Article  CAS  PubMed  Google Scholar 

Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.

Article  CAS  PubMed  Google Scholar 

Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18:1427–31.

Article  CAS  PubMed  Google Scholar 

Pu W, Wang C, Chen S, Zhao D, Zhou Y, Ma Y, et al. Targeted bisulfite sequencing identified a panel of DNA methylation-based biomarkers for esophageal squamous cell carcinoma (ESCC). Clin Epigenetics. 2017;9:129.

Article  PubMed  PubMed Central  Google Scholar 

Li Z, Chen P, Su R, Li Y, Hu C, Wang Y, et al. Overexpression and knockout of miR-126 both promote leukemogenesis. Blood. 2015;126:2005–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin ZB, Hirokawa G, Gui L, Takahashi R, Osakada F, Hiura Y, et al. Targeted deletion of miR-182, an abundant retinal microRNA. Mol Vis. 2009;15:523–33.

CAS  PubMed  PubMed Central  Google Scholar 

Jeon YK, Min HS, Lee YJ, Kang BH, Kim EJ, Park HJ, et al. Targeting of a developmentally regulated epitope of CD43 for the treatment of acute leukemia. Cancer Immunol Immunother. 2011;60:1697–706.

Article  CAS  PubMed  Google Scholar 

Chen C, Hao X, Lai X, Liu L, Zhu J, Shao H, et al. Oxidative phosphorylation enhances the leukemogenic capacity and resistance to chemotherapy of B cell acute lymphoblastic leukemia. Sci Adv. 2021;7:eabd6280.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347:70–8.

Article  CAS  PubMed  Google Scholar 

Junker F, Chabloz A, Koch U, Radtke F. Dicer1 imparts essential survival cues in Notch-driven T-ALL via miR-21-mediated tumor suppressor Pdcd4 repression. Blood. 2015;126:993–1004.

Article  CAS  PubMed  Google Scholar 

Li Z, Zhang Z, Li Y, Arnovitz S, Chen P, Huang H, et al. PBX3 is an important cofactor of HOXA9 in leukemogenesis. Blood. 2013;121:1422–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic subclones confer resistance to Venetoclax-based therapy in patients with acute myeloid Leukemia. Cancer Discov. 2020;10:536–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan D, Dong XD, Chen X, Yao S, Wang L, Wang J, et al. Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. PLoS ONE. 2012;7:e40967.

Article  CAS  PubMed  PubMed Central  Google Scholar